Remove 2001 Remove Doctors Remove Marketing Remove Pharmaceuticals
article thumbnail

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China

The Pharma Data

21, 2020 (GLOBE NEWSWIRE) — Shanghai Haini Pharmaceutical Co., They are one of the top pharmaceutical firms in China and are considered a market leader in the antibiotics space. There is an urgent need in China, and indeed, globally, to bring new antibiotics to the market that can address critical resistance issues.

article thumbnail

Chipscreen and HISUN reach a strategic cooperation

The Pharma Data

(hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation. SH) was founded in Shenzhen on 2001, specializing in the research and development of novel small molecule drugs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Women in Stem with Dr Sara Sangha

Drug Target Review

As a female undergraduate student studying pharmaceutical sciences, one of the biggest challenges was not having enough female leaders as mentors. Since joining Allergan Aesthetics in 2001, my role in medical affairs has always focused, in one way or another, on supporting the journey of a drug/device from bench to bedside.

article thumbnail

What to expect from PEGS Europe 2023: Day 2

Drug Discovery World

Alessa Schaffrath, Doctoral Student, UKE Hamburg, on: ‘Transgenic llama mice – a fast and flexible single domain discovery tool’. Dimitris Skokos, PhD, Senior Director, Cancer Immunology, Regeneron Pharmaceuticals, on: ‘Tumour-targeted costimulation via CD28 bispecific antibodies: Turning immunotherapy “cold” tumours “hot”’.

article thumbnail

Another Update on Medical Abortion Litigation

Drug & Device Law

FDA litigation, back in April, the United States Supreme Court had just stayed what we described as “a truly ridiculous decision purporting to invalidate a number of actions taken by FDA with regard to mifepristone, the only currently marketed approved medication for medical abortion.” 341 (2001), is so important. See Enriquez v.

FDA 52
article thumbnail

Another Update on Medical Abortion Litigation

Drug & Device Law

FDA litigation, back in April, the United States Supreme Court had just stayed what we described as “a truly ridiculous decision purporting to invalidate a number of actions taken by FDA with regard to mifepristone, the only currently marketed approved medication for medical abortion.” 341 (2001), is so important. See Enriquez v.

article thumbnail

Another RICOdiculous Decision

Drug & Device Law

We’ve discussed recently how a federal statute intended to allow suits against international terrorists has been misapplied as allowing suits against pharmaceutical companies. Takeda Pharmaceuticals Co. , 341 (2001). Takeda Pharmaceutical Co. , 3d 1243 (9th Cir. Plaintiffs Legal Committee , 531 U.S.